Skye Bioscience establishes metabolic clinical, scientific advisory board

Skye Bioscience announced the formation of its clinical advisory board, CAB, gathering renowned academics and world-class metabolic disease experts, particularly in the field of obesity. The CAB will work closely with management to provide strategic and scientific counsel to support the development of the Company’s lead candidate, Nimacimab, a cannabinoid 1 receptor inhibitor, which is expected to enter a Phase 2 trial in individuals with obesity in Q3 2024. Members of the Clinical and Scientific Advisory Board include: Lee Kaplan, MD, Ph.D., Louis Aronne, MD, Rekha Kumar, MD, M.S., Marcus DaSilva Goncalves, MD, Ph.D., Beverly Tchang, MD, Eduardo Munoz, MD, Ph.D., Giovanni Appendino, Ph.D.